Brain Tumor News and Research RSS Feed - Brain Tumor News and Research

A Brain Tumor is the growth of abnormal cells in the tissues of the brain. Brain tumors can be benign (not cancer) or malignant (cancer).
Indian hospital treats 10,000th patient using RapidArc radiotherapy technology

Indian hospital treats 10,000th patient using RapidArc radiotherapy technology

A three-year-old baby girl with a brain tumor has become the 10,000th patient at Yashoda Hospital in Hyderabad, India to be treated using RapidArc radiotherapy technology from Varian Medical Systems. [More]
Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

According to analysis from business intelligence provider GBI Research - Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - the value of the global Glioblastoma Multiforme (GBM) treatment market will expand at a rapid Compound Annual Growth Rate (CAGR) of 10.9%, from $301 million in 2013 to $623 million by 2020. [More]
Detroit-area patients contribute to national study that redefines diagnosis, treatment of glioma

Detroit-area patients contribute to national study that redefines diagnosis, treatment of glioma

Sixty-seven patients from the Hermelin Brain Tumor Center at Henry Ford Hospital and their families made important contributions to a national cancer study that proposes a change in how some brain tumors are classified - and ultimately treated. [More]
Discovery may help scientists attack the root of deadliest brain tumors

Discovery may help scientists attack the root of deadliest brain tumors

Some brain tumors are notoriously difficult to treat. Whether surgically removed, zapped by radiation or infiltrated by chemotherapy drugs, they find a way to return. The ability of many brain tumors to regenerate can be traced to cancer stem cells that evade treatment and spur the growth of new tumor cells. [More]
New approach to classifying brain tumors could lead to significant improvements in diagnosis, treatment

New approach to classifying brain tumors could lead to significant improvements in diagnosis, treatment

A Case Comprehensive Cancer Center brain surgeon and neurosurgery professor is among the primary authors of a new approach to classifying tumors that could lead to significant improvements in their diagnosis and treatment. The research and recommendations appear online June 10 in The New England Journal of Medicine. [More]
Data from statewide quality collaborative helps surgeons to reduce rates of serious trauma complication

Data from statewide quality collaborative helps surgeons to reduce rates of serious trauma complication

As health insurers place more emphasis on paying for quality outcomes rather than for specific services provided by doctors and hospitals, several quality improvement programs have been developed as a way to help health care providers identify problem areas and share best practices. While some studies have evaluated how well these quality improvement programs achieve their goals, not many have focused on the area of trauma care. [More]
Researchers generate computer models for targeted drug therapy on DIPG cancer cells

Researchers generate computer models for targeted drug therapy on DIPG cancer cells

The results of a recent study on targeted therapy of a specific type of brain cancer were published by Nature Medicine showing specific progress in cancer treatment. [More]
Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Seattle Children's opens enrollment for first clinical trial of Tumor Paint BLZ-100 for children with brain tumors

Seattle Children's today announced the opening of patient enrollment for the first clinical research trial of the drug Tumor Paint BLZ-100, which is designed to improve surgical outcomes in children with brain tumors – the most common solid tumor cancer in kids. [More]
New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

New findings suggest that a gene called IDH1 might be prognostic marker for a rare form of brain cancer. Patients in this study who had a mutated IDH gene lived an average of 7.9 years after diagnosis versus 2.8 years for patients with unaltered IDH. [More]
Modified poliovirus therapy for glioblastoma works best at a low dosage

Modified poliovirus therapy for glioblastoma works best at a low dosage

A modified poliovirus therapy that is showing promising results for patients with glioblastoma brain tumors works best at a low dosage, according to the research team at Duke's Preston Robert Tisch Brain Tumor Center where the investigational therapy is being pioneered. [More]
Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients. [More]
Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

Additional preclinical data on DelMar’s VAL-083 to treat temozolomide-resistant GBM presented at AACR

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, presented additional preclinical data at the American Association of Cancer Research (AACR) Advances in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM). [More]
Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Brain Tumor Biotech Summit held in Manhattan on 29 May, 2015

Voices Against Brain Cancer, a national non-profit organization committed to finding a cure for brain cancer and brain tumors, and the Feinstein Institute for Medical Research in Long Island, will be hosting a Brain Tumor Biotech Summit on Friday, May 29th, 2015 at Lenox Hill Hospital's Einhorn Auditorium in Manhattan. [More]
Wings of Courage: New book pays tribute to Livonia girl who fought cancer

Wings of Courage: New book pays tribute to Livonia girl who fought cancer

Leah James loved the color purple, Nemo and storybooks. She was also well known for her contagious smile and the phrase "my heart is happy" even when she was fighting cancer at age four. [More]
Researchers identify chemical pathway associated with seizures, shorter survival in patients with malignant glioma

Researchers identify chemical pathway associated with seizures, shorter survival in patients with malignant glioma

Researchers at the University of Alabama at Birmingham have identified a chemical pathway that may be associated with seizures and shorter patient survival in some patients with malignant glioma, the most common and deadly form of brain tumor. In findings published May 27 in Science Translational Medicine, the researchers suggest that a transporter known as SXC is responsible for boosting levels of glutamate in the brains of some glioma patients. [More]
Tiny drug-delivery system can help identify brain tumor types through 'virtual biopsies'

Tiny drug-delivery system can help identify brain tumor types through 'virtual biopsies'

Biomedical researchers at Cedars-Sinai have invented a tiny drug-delivery system that can identify cancer cell types in the brain through "virtual biopsies" and then attack the molecular structure of the disease. [More]
DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

DNAtrix signs agreement to utilize Alcyone's MEMS platform for direct drug delivery into glioblastoma

Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM). [More]
Blood-thinning treatment safe for patients with brain metastases

Blood-thinning treatment safe for patients with brain metastases

Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a study, published online today in Blood, the Journal of the American Society of Hematology. [More]
Researchers identify three genes involved in choroid plexus carcinoma

Researchers identify three genes involved in choroid plexus carcinoma

Researchers have identified three genes that play a pivotal role in the brain tumor choroid plexus carcinoma (CPC), a discovery that lays the groundwork for more effective treatment of this rare, often fatal cancer. St. Jude Children's Research Hospital scientists led the study, which appears today in the journal Cancer Cell. [More]
Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center, the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells. [More]
Advertisement
Advertisement